Literature DB >> 16997860

Priming by tumor necrosis factor-alpha of human neutrophil NADPH-oxidase activity induced by anti-proteinase-3 or anti-myeloperoxidase antibodies.

Dominique Reumaux1, Peter L Hordijk, Patrick Duthilleul, Dirk Roos.   

Abstract

Anti-proteinase-3 (anti-PR3) or anti-myeloperoxidase (anti-MPO) antibodies are capable of activating human neutrophils primed by TNF-alpha in vitro. We described previously the involvement of FcgammaRIIa and beta(2) integrins in this neutrophil activation. In the literature, the requirement of TNF priming has been attributed to an effect of TNF-alpha on the expression of PR3 or MPO on the cell surface. Under our experimental conditions, TNF-alpha (2 ng/ml) increased the binding of the antibody against PR3, whereas binding of the antibody against MPO could hardly be detected, not even after TNF-alpha treatment. The aim of this study was to consider (an)other(s) role(s) for TNF-alpha in facilitating the NADPH-oxidase activation by these antibodies. We demonstrate the early mobilization of the secretory vesicles as a result of TNF-induced increase in intracellular-free calcium ions, the parallel colocalization of gp91(phox), the main component of the NADPH oxidase with beta(2) integrins and FcgammaRIIa on the neutrophil surface, and the FcgammaRIIa clustering upon TNF priming. TNF-alpha also induced redistribution of FcgammaRIIa to the cytoskeleton in a dose- and time-dependent manner. Moreover, blocking CD18 MHM23 antibody, cytochalasin B, and D609 (an inhibitor of phosphatidylcholine phospholipase C) inhibited this redistribution and the respiratory burst in TNF-treated neutrophils exposed to anti-PR3 or anti-MPO antibodies. Our results indicate direct effects of TNF-alpha in facilitating neutrophil activation by these antibodies and further support the importance of cytoskeletal rearrangements in this priming process.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16997860     DOI: 10.1189/jlb.0304144

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  6 in total

1.  Inhibition of neutrophil function by two tick salivary proteins.

Authors:  Xiuyang Guo; Carmen J Booth; Michael A Paley; Xiaomei Wang; Kathleen DePonte; Erol Fikrig; Sukanya Narasimhan; Ruth R Montgomery
Journal:  Infect Immun       Date:  2009-03-30       Impact factor: 3.441

Review 2.  Endothelium-neutrophil interactions in ANCA-associated diseases.

Authors:  Lise Halbwachs; Philippe Lesavre
Journal:  J Am Soc Nephrol       Date:  2012-09       Impact factor: 10.121

3.  Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands.

Authors:  Eui-Sang Chung; Sunil Kumar Chauhan; Yiping Jin; Shintaro Nakao; Ali Hafezi-Moghadam; Nico van Rooijen; Qiang Zhang; Lu Chen; Reza Dana
Journal:  Am J Pathol       Date:  2009-10-01       Impact factor: 4.307

Review 4.  Pathogenicity of Proteinase 3-Anti-Neutrophil Cytoplasmic Antibody in Granulomatosis With Polyangiitis: Implications as Biomarker and Future Therapies.

Authors:  Jérôme Granel; Brice Korkmaz; Dalila Nouar; Stefanie A I Weiss; Dieter E Jenne; Roxane Lemoine; Cyrille Hoarau
Journal:  Front Immunol       Date:  2021-02-18       Impact factor: 7.561

5.  Activity-based protein profiling guided identification of urine proteinase 3 activity in subclinical rejection after renal transplantation.

Authors:  Mario Navarrete; Brice Korkmaz; Carla Guarino; Adam Lesner; Ying Lao; Julie Ho; Peter Nickerson; John A Wilkins
Journal:  Clin Proteomics       Date:  2020-06-16       Impact factor: 3.988

6.  4C3 Human Monoclonal Antibody: A Proof of Concept for Non-pathogenic Proteinase 3 Anti-neutrophil Cytoplasmic Antibodies in Granulomatosis With Polyangiitis.

Authors:  Jérôme Granel; Roxane Lemoine; Eric Morello; Yann Gallais; Julie Mariot; Marion Drapeau; Astrid Musnier; Anne Poupon; Martine Pugnière; Seda Seren; Dalila Nouar; Valérie Gouilleux-Gruart; Hervé Watier; Brice Korkmaz; Cyrille Hoarau
Journal:  Front Immunol       Date:  2020-09-25       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.